Marieke van Son

57 MRI-GUIDED ULTRAFOCAL HDR-BRACHYTHERAPY REFERENCES 1. Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. Contempo- rary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009 Sep 16;101(18):1280-1283. 2. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Pros- tate Cancer. N Engl J Med 2016 Oct 13;375(15):1415-1424. 3. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Mon- itoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2016 Oct 13;375(15):1425-1437. 4. Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and Established Technology in Focal Ab- lation of the Prostate: A Systematic Review. Eur Urol 2017 Jan;71(1):17-34. 5. Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, et al. Updat- ed results of magnetic resonance imag- ing guided partial prostate brachyther- apy for favorable risk prostate cancer: implications for focal therapy. J Urol 2012 Oct;188(4):1151-1156. 6. Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, et al. A Mul- ticentre Study of 5-year Outcomes Fol- lowing Focal Therapy in Treating Clini- cally Significant Nonmetastatic Prostate Cancer. Eur Urol 2018 Oct;74(4):422-429. 7. Maenhout M, Peters M, Moerland MA, Meijer RP, van den BoschMAAJ, Frank SJ, et al. MRI guided focal HDR brachyther- apy for localized prostate cancer: Tox- icity, biochemical outcome and quality of life. Radiother Oncol 2018 Aug 18. 8. Maenhout M, van der Voort van Zyp,J.R.N., Borot de Battisti M, Peters M, van Vulpen M, van den Bosch M, et al. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer. Brachytherapy 2018 Jan - Feb;17(1):68-77. 9. Groenendaal G, Moman MR, Korporaal JG, van Diest PJ, van Vulpen M, Philip- pens ME, et al. Validation of functional imaging with pathology for tumor delin- eation in the prostate. Radiother Oncol 2010 Feb;94(2):145-150. 10. Holly R, Morton GC, Sankreacha R, Law N, Cisecki T, Loblaw DA, et al. Use of cone-beam imaging to correct for cath- eter displacement in high dose-rate prostate brachytherapy. Brachytherapy 2011 Jul-Aug;10(4):299-305. 11. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quali- ty-of-life instrument for use in interna- tional clinical trials in oncology. J Natl Cancer Inst 1993 Mar 3;85(5):365-376. 12. Aaronson NK, Muller M, Cohen PD, Es- sink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norm- ing of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epi- demiol 1998 Nov;51(11):1055-1068. 13. van Andel G, Bottomley A, Fossa SD, Effi- cace F, Coens C, Guerif S, et al. An inter- national field study of the EORTC QLQ- PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008 Nov;44(16):2418-2424. 14. OsobaD, RodriguesG, Myles J, ZeeB, Pater J. Interpreting the significance of chang- es in health-related quality-of-life scores. J Clin Oncol 1998 Jan;16(1):139-144. 3